Seattle Genetics Reports Second Quarter 2018 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/24/2026
- Nasdaq, S&P end lower as tech stocks fall
- Micron posts record profit as AI memory demand fuels explosive growth
- Brent settles at lowest since before start of Iran war as more tankers exit Hormuz
- All eyes on Micron earnings tonight as sell-off raises stakes for AI memory trade
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Rescue work underway after quakes rock Venezuela, 'high casualties' likely
- Needham Starts NeoVolta (NEOV) at Buy
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- NextEra to discuss paying about $76 per share for Dominion, Bloomberg News reports
- Campbell Soup (CPB) Declares $0.39 Quarterly Dividend; 7.7% Yield
Seattle Genetics (SGEN) PT Raised to $79 at Needham & Company
July 27, 2018 12:22 PM EDTNeedham & Company raised its price target on Seattle Genetics (NASDAQ: SGEN) to $79.00 (from $74.00) while maintaining a Buy rating.
Analyst Chad Messer commented, "Seattle handily beat Street consensus with 2Q:18 ADCETRIS sales of $122M, higher than our $109M and similar Street... More
Seattle Genetics (SGEN) PT Raised to $64 at Cowen
July 27, 2018 11:29 AM EDTCowen raised its price target on Seattle Genetics (NASDAQ: SGEN) to $64.00 (from $54.00) while maintaining a Outperform rating
Analyst Boris Peaker noted strength was driven by strong adoption in the frontline HL by community docs, although he said the recent stock run-up factors in this stronger uptake.
... MoreSeattle Genetics (SGEN) PT Raised to $81 at SunTrust Robinson Humphrey
July 27, 2018 8:05 AM EDTSunTrust Robinson Humphrey raised its price target on Seattle Genetics (NASDAQ: SGEN) to $81.00 (from $80.00) while maintaining a Buy rating.
Analyst Yatin Suneja commented, "Adcetris surprised with another stronger than expected 2Q18 sales (+14%/$14.8MM vs. consensus), on robust uptake in frontline (1L) cHL.... More
Seattle Genetics (SGEN) Reports Q2 EPS of $0.47, Revenues Beat; Offers FY18 Outlook
July 26, 2018 4:05 PM EDTSeattle Genetics (NASDAQ: SGEN) reported Q2 EPS of $0.47, versus ($0.39) reported last year. Revenue for the quarter came in at $170.17 million versus the consensus estimate of $141.07 million.
Our ADCETRIS sales growth in the first full quarter following FDA approval in frontline Stage III or IV classical Hodgkin lymphoma demonstrates a strong reception from the oncology... More
